Steering Committee

Co-Chairs:

Lewis J. Rubin, M.D., FACP, FCCP, FAHA, FRCP

University of California, San Diego, California, USA

Emeritus Professor of Medicine UCSD School of Medicine

Emeritus Director of Pulmonary and Critical Care

Lewis J. Rubin, M.D., FACP, FCCP, FAHA, FRCP, is Emeritus Professor of Medicine at the University of California in San Diego, School of Medicine and its Emeritus Director of Pulmonary and Critical Care. Professor Rubin earned his medical degree from the Albert Einstein College of Medicine, New York, and completed a residency and fellowship at Duke University Medical Center. He has since had a distinguished career, being involved in the basic and clinical investigation of pulmonary vascular diseases for almost 30 years. He is co-author of nearly 200 peer-reviewed publications, more than 60 book chapters, and editor of five books on pulmonary circulation. He has served as the Principal Investigator/Steering Committee Chair for the pivotal trials of epoprostenol, treprostinil, bosentan and ambrisentan, and on the Steering Committee for the pivotal trials of iloprost and sildenafil in pulmonary hypertension. He has received numerous honors and awards, including being named an Honorary Fellow by the Royal College of Physicians, United Kingdom.



Ganesh Raghu, M.D., FCCP, FACP

University of Washington, Seattle, WA

Professor of Medicine & Lab Medicine

Division of Pulmonary & Critical Care Medicine Director, Interstitial Lung Disease, Sarcoid and Pulmonary Fibrosis Program Medical Director Lung Transplant Program

Dr. Raghu is a professor of medicine in the Division of Pulmonary and Critical Care Medicine at the University of Washington (UW) and director of the Interstitial Lung Disease/Sarcoid/Pulmonary Fibrosis Program as well as Co-Director of Scleroderma clinic at the UW Medical Center, Seattle, WA. He is also medical director of the UW's Lung Transplant Program and holds an adjunct appointment in the Department of Laboratory Medicine at UW, Seattle, WA.

He earned his medical degree from Mysore Medical College in India. After an internship there, he went to the University of Newcastle Upon Tyne in Hartlepool, UK, for a residency in general medicine and chest medicine. He then moved to State University of NY (SUNY) at Buffalo, NY, where he was chief medical resident. He came to the UW in 1981 for a fellowship in pulmonary and critical care medicine and then also completed a fellowship in lung cell biology here before joining the faculty in the department of medicine. He is board-certified in internal medicine and critical care medicine.

 

Scientific Advisors

Members:

Kevin K. Brown, M.D., FCCP

National Jewish Health; Denver, CO

Professor and Vice Chairman, Department of Medicine Director, Interstitial Lung Disease Program


Dr. Kevin K. Brown is a Professor and Vice Chairman in the Department of Medicine and Clinical Director of the Interstitial Lung Disease Program at National Jewish Health. His clinical and research interests include the evaluation and treatment of interstitial lung disease and the biologic mechanisms responsible for the development and progression of pulmonary fibrosis.



Vallerie V. McLaughlin, M.D., FACCP, FACC, FAHA

University of Michigan Cardiovascular Center; Ann Arbor, MI

Professor of Internal Medicine Director, Pulmonary Hypertension Program


Dr. McLaughlin received her bachelor’s degree in Biomedical Engineering at Northwestern University, Technologic Institute, Evanston, Illinois, and her Doctor of Medicine from Northwestern University Medical School, Chicago, Illinois. Upon completion of her residency in Internal Medicine at the University of Michigan and her fellowship in cardiovascular diseases at Northwestern University, she served as Associate Director of the Center for Pulmonary Heart Disease at Rush University in Chicago. She is currently the Director of the Pulmonary Hypertension Program in the Division of Cardiovascular Medicine at the University of Michigan in Ann Arbor, Michigan. Dr. McLaughlin is also Professor of Medicine.

Dr. McLaughlin is a fellow in the American College of Cardiology, the American College of Chest Physicians, and the American Heart Association. She is a member of the American Thoracic Society, the Scientific Leadership Committee of the Pulmonary Hypertension Association, and the American College of Chest Physicians Pulmonary Hypertension Guidelines Panel. Dr. McLaughlin is a past editor-in-chief of Advances in Pulmonary Hypertension, the Official Journal of the Pulmonary Hypertension Association, and a past chairperson of the American Heart Association Women in Cardiology Committee. She has served as a member of the American College of Cardiology Scientific Program Committee and served as the Chairperson for the American College of Cardiology/American Heart Associate Clinical Expert Consensus Document on Pulmonary Hypertension. Dr. McLaughlin is the immediate past Chairperson of the Pulmonary Hypertension Association Scientific Leadership Council and is the Chair-Elect of the Pulmonary Hypertension Association Board of Trustees.

She is frequently an invited lecturer at national and international conferences on the topic of Pulmonary Hypertension. She is author of numerous peer-reviewed articles and book chapters.

Steven D. Nathan, M.D., FCCP

Inova Fairfax Hospital; Falls Church, VA

Medical Director, Lung Transplant Program

Director, Advanced Lung Disease Program


Steven D. Nathan, M.D., is the Director of the Advanced Lung Disease Program and the Medical Director of the Lung Transplant Program at Inova Fairfax Hospital in Falls Church, Virginia. He is also the Co-Director of the NIH-Inova Advanced Lung Disease Program. He is an Affiliate Professor of Biomedical Sciences at George Mason University and Associate Professor of Medicine at Virginia Commonwealth University. Dr. Nathan received his medical degree at the University of the Witwatersrand Medical School in Johannesburg, South Africa. He completed his internship in Internal Medicine and General Surgery at the Johannesburg Hospital. Dr. Nathan performed his Internal Medicine residency at Long Island Jewish Hospital in New York City, and completed his fellowships in Pulmonary Medicine, Critical Care, and Lung Transplantation at Cedars-Sinai Medical Center in Los Angeles, California. He is board certified in Internal Medicine, Pulmonary Diseases, and Critical Care Medicine.

Dr. Nathan has over 200 publications including original research manuscripts, abstracts, reviews and book chapters. He has been a leader in the area of pulmonary hypertension complicating parenchymal lung disease. He has received a number of awards for clinical and research excellence and has spoken at numerous national and international conferences. He is a member of several professional medical associations, including the American Thoracic Society, the American College of Chest Physicians and the International Society for Heart and Lung Transplantation.